Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide in Recurrent Malignant Glioma
NCT00006080Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2000
- Primary completion
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fenretinide in malignant glioma, glioblastoma multiforme (GBM), Gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2000; status: completed.
02
Drugs
fenretinide
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)Gliosarcoma (GS)anaplastic astrocytoma (AA)anaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT00006080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006080.